Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 10/20 | 0.65 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.43 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6521235 | 1.00 | ZAP70 (0.65) | ZAP70JAK2SYKTTBK1TTBK2 | |
| SCHEMBL1158518 | 0.87 | ZAP70 (0.60) | ZAP70JAK2TP53MAPTMAPK1 | |
| SCHEMBL1048365 | 0.81 | ZAP70 (0.67) | ZAP70JAK2SYKTTBK1TTBK2 | |
| SCHEMBL1049032 | 0.80 | ZAP70 (0.72) | ZAP70JAK2SYKTTBK1TTBK2 | |
| SCHEMBL1044792 | 0.79 | ZAP70 (1.00) | ZAP70JAK2SYK | |
| SCHEMBL1158387 | 0.79 | ZAP70 (0.53) | ZAP70JAK2SYKBTK | |
| SCHEMBL6521455 | 0.79 | ZAP70 (0.53) | ZAP70JAK2SYKBTK | |
| SCHEMBL1158484 | 0.78 | ZAP70 (0.79) | ZAP70JAK2SYKTTBK1TTBK2 | |
| SCHEMBL6524306 | 0.77 | ZAP70 (0.69) | ZAP70JAK2SYKTTBK1TTBK2 | |
| SCHEMBL1158853 | 0.77 | ZAP70 (0.83) | ZAP70JAK2SYKTTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459556-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-06-06 | — | — | EP | claimed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | claimed |
| EP-2459556-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-06-06 | — | — | EP | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | ZAP70 5/4885JAK2 19/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.